ZimVie (NASDAQ:ZIMV) Upgraded by Barclays to Equal Weight Rating

Barclays upgraded shares of ZimVie (NASDAQ:ZIMV - Free Report) from an underweight rating to an equal weight rating in a research note issued to investors on Tuesday morning, MarketBeat.com reports. Barclays currently has $19.00 price objective on the stock, up from their prior price objective of $9.00.

A number of other brokerages have also recently issued reports on ZIMV. B. Riley began coverage on shares of ZimVie in a report on Thursday, April 10th. They set a "buy" rating and a $16.00 target price on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ZimVie in a research note on Wednesday, April 9th. UBS Group dropped their price objective on ZimVie from $16.00 to $10.00 and set a "neutral" rating on the stock in a report on Thursday, May 15th. Finally, Wall Street Zen lowered ZimVie from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

ZimVie Stock Performance

Shares of NASDAQ ZIMV traded down $0.01 during trading on Tuesday, reaching $18.73. 285,881 shares of the stock traded hands, compared to its average volume of 249,256. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.14 and a quick ratio of 1.48. The stock has a market capitalization of $521.49 million, a P/E ratio of -26.37 and a beta of 2.07. ZimVie has a 52-week low of $8.15 and a 52-week high of $22.04. The company has a 50-day moving average of $9.85 and a 200-day moving average of $11.07.

ZimVie (NASDAQ:ZIMV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.06. The business had revenue of $112.00 million for the quarter, compared to analysts' expectations of $113.10 million. ZimVie had a positive return on equity of 5.53% and a negative net margin of 4.40%. Analysts forecast that ZimVie will post 0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZIMV. J. Goldman & Co LP boosted its stake in ZimVie by 167.5% during the fourth quarter. J. Goldman & Co LP now owns 1,425,810 shares of the company's stock valued at $19,890,000 after buying an additional 892,785 shares during the period. Neuberger Berman Group LLC boosted its position in shares of ZimVie by 1.7% during the 1st quarter. Neuberger Berman Group LLC now owns 1,332,890 shares of the company's stock valued at $14,435,000 after acquiring an additional 22,075 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ZimVie by 9.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,244,938 shares of the company's stock worth $17,367,000 after purchasing an additional 107,461 shares in the last quarter. Millennium Management LLC grew its holdings in shares of ZimVie by 7.7% during the first quarter. Millennium Management LLC now owns 707,771 shares of the company's stock worth $7,644,000 after purchasing an additional 50,805 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of ZimVie by 10.0% in the first quarter. American Century Companies Inc. now owns 690,675 shares of the company's stock worth $7,459,000 after purchasing an additional 62,625 shares during the last quarter. Institutional investors own 95.63% of the company's stock.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.